HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patrick Angibaud Selected Research

quisinostat

11/2009JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patrick Angibaud Research Topics

Disease

5Neoplasms (Cancer)
01/2017 - 11/2009
3Neoplasm Metastasis (Metastasis)
01/2017 - 11/2009
1Lung Neoplasms (Lung Cancer)
01/2016
1Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
01/2016
1Carcinoma (Carcinomatosis)
11/2009
1Hematologic Neoplasms (Hematological Malignancy)
11/2009

Drug/Important Bio-Agent (IBA)

2Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2017 - 09/2011
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2017 - 09/2011
2Histone Deacetylase InhibitorsIBA
01/2010 - 11/2009
2Histone Deacetylases (Histone Deacetylase)IBA
01/2010 - 11/2009
1erdafitinibIBA
01/2017
1CytokinesIBA
01/2016
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2016
1TankyrasesIBA
01/2016
1AcidsIBA
01/2010
1Leucovorin (Folinic Acid)FDA Link
11/2009
1Histones (Histone)IBA
11/2009
1Proteins (Proteins, Gene)FDA Link
11/2009
1quisinostatIBA
11/2009
1Fluorouracil (Carac)FDA LinkGeneric
11/2009